Angiochem Announces Presentations at Three Upcoming Conferences

Montreal, Canada, May 17, 2012 – Angiochem, a clinical stage biotechnology company, today announced presentations at three upcoming biotechnology conferences: • TIDES® Oligneotides and Peptides, Research, Technology and Product Development Conference

o May 20-23, 2012, Las Vegas, NV: Jean Lachowicz Ph.D., Chief Scientific Officer of Angiochem will present “EPiC Technology: Using Peptides to Physiologically Cross the BBB” in a session on Innovations in Cell-Penetrating and Membrane-Permeating Peptides • BIOFinance 2012 o May 29-30, 2012, Toronto, Canada: Jean Paul Castaigne, MD, President and CEO of Angiochem will provide a company update • Boston Biotech CEO Conference o June 11-12, 2012, Boston, MA: Jean Paul Castaigne, MD, will participate in a panel discussion on Building Technology Value About Angiochem Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new EPiC compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.